Print
12 February 2018
GMP News
NovaMedica, a Russian pharmaceutical company and the investment project of RUSNANO, has announced the collaboration in the area of knowledge and technology transfer between NovaMedica Innotech, an R&D center, and Evonik, a German company and a leader in the global market of excipients for pharmaceutical industry.
This partnership will result in the establishment of a training center for the transfer of competencies in the area of pharmaceutical technology, which will be created in NovaMedica Innotech in Russia.
The coaches of Evonik will provide to the specialists of NovaMedica R&D the knowledge and technology on the use of excipients for designing the innovative properties of drugs. For example, these methods and substances are required in order to ensure the prolonged action of medicinal product, delayed release of the active ingredient, or its targeted delivery to the desired part of gastrointestinal tract, as well as to manufacture the injectable dosage forms with prolonged action and implants, liposomal and injectable nanosomal forms, pharmacopoeial amino acids, ingredients for improving the efficacy of nutrient environments in biotech processes, etc. After the training, the specialists of NovaMedica will transfer the obtained knowledge to their colleagues in Russian pharmaceutical companies.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.